The potential molecular markers of inflammatory response in KOA with AD based on single-cell transcriptome sequencing analysis and identification of ligands by virtual screening
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10854-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Yufeng Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Traditional Chinese Medicine Hospital of Zhongshan, Zhongshan, 528400, Guangdong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Osteoarthritis, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Basic and Applied Basic Research Project of Guangdong Province, Basic and Applied Basic Research Project of Province-Enterprise Joint Fund General Project of Guangdong Province.
Abstract (Originalsprache)
Alzheimer's disease (AD) and osteoarthritis (OA) are both senile degenerative diseases. Clinical studies have found that OA patients have a significantly increased risk of AD in their later life. This study hypothesized that chronic aseptic inflammation might lead to AD in KOA patients. However, current research has not yet clarified the potential mechanism between AD and KOA. Therefore, this study intends to use KOA transcriptional profiling and single-cell sequencing analysis technology to explore the molecular mechanism of KOA affecting AD development, and screen potential molecular biomarkers and drugs for the prediction, diagnosis, and prognosis of AD in KOA patients. It was found that the higher the expression of TXNIP, MMP3, and MMP13, the higher the risk coefficient of AD was. In addition, the AUC of TXNIP, MMP3, and MMP13 were all greater than 0.70, which had good diagnostic significance for AD. Finally, through the virtual screening of core proteins in FDA drugs and molecular dynamics simulation, it was found that compound Cobicistat could be targeted to TXNIP, Itc could be targeted to MMP3, and Isavuconazonium could be targeted to MMP13. To sum up, TXNIP, MMP3, and MMP13 are prospective molecular markers in KOA with AD, which could be used to predict, diagnose, and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Traditional Chinese Medicine Hospital of Zhongshan, Zhongshan, 528400, Guangdong, China.
- Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
- The Fifth Clinical College of Guangzhou, University of Chinese Medicine, Guangzhou, 510095, China.
- Guangdong Provincial Second Hospital of Traditional Chinese Medicine (Guangdong Provincial Engineering Technology Research Institute of Traditional Chinese Medicine), Guangzhou, 510095, China.
- Guangzhou Orthopedic Hospital, Guangdong Province, Guangzhou University of Chinese Medicine, Guangzhou, 510045, China.
- The First Clinical Medical College, Guangdong Province, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Förderung
- Basic and Applied Basic Research Project of Guangdong Province
- Basic and Applied Basic Research Project of Province-Enterprise Joint Fund General Project of Guangdong Province
Zitieren
APA
Wu, Y., Chen, W., Jian, J., Liu, W., Wang, H., Gao, D., & Liu, W. (2025). The potential molecular markers of inflammatory response in KOA with AD based on single-cell transcriptome sequencing analysis and identification of ligands by virtual screening. Molecular Diversity. https://doi.org/10.1007/s11030-024-10854-4
Vancouver
Wu Y, Chen W, Jian J, Liu W, Wang H, Gao D, et al. The potential molecular markers of inflammatory response in KOA with AD based on single-cell transcriptome sequencing analysis and identification of ligands by virtual screening. Molecular Diversity. 2025. doi:10.1007/s11030-024-10854-4
BibTeX
@article{Wu2025,
author = {Wu, Yufeng and Chen, Weijian and Jian, Junde and Liu, Weinian and Wang, Haibin and Gao, Dawei and Liu, Wengang},
title = {The potential molecular markers of inflammatory response in KOA with AD based on single-cell transcriptome sequencing analysis and identification of ligands by virtual screening},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10854-4}
}
EUVIMED